Preliminary studies suggested HGSOC patients with BRCA1 mutations demonstrated higher CD8+ TILs, and neoantigen load might explain higher CD8+ TILs (39, 40), which is consistent with patients with low TMErisk scores exhibiting more neoantigens and an increased number of tumor-infiltrating lymphocytes. The gene discussed is CD8A; the disease is neoplasm.